CSBIO: The clinical trial application for Aibennape injection for weight loss indications has been approved
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, CSBIO announced that the company and its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. (referred to as "Changshan Kaijiejian") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for the jointly declared Aibennape injection for weight loss indications has been approved
According to the Zhitong Finance APP, CSBIO (300255.SZ) announced that the company and its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. (referred to as "Changshan Kaijiejian") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration (NMPA). The clinical trial application for the injection of Aibennapeptide for weight loss indications, jointly submitted by both parties, has been approved